- Home
- SBLK vs BLTE Comparison
SBLK vs BLTE Comparison
Compare SBLK & BLTE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SBLK
- BLTE
- Stock Information
- Founded
- SBLK 2006
- BLTE 2018
- Country
- SBLK Greece
- BLTE United States
- Employees
- SBLK N/A
- BLTE N/A
- Industry
- SBLK Marine Transportation
- BLTE Biotechnology: Pharmaceutical Preparations
- Sector
- SBLK Consumer Discretionary
- BLTE Health Care
- Exchange
- SBLK Nasdaq
- BLTE Nasdaq
- Market Cap
- SBLK 2.2B
- BLTE 2.1B
- IPO Year
- SBLK N/A
- BLTE 2022
- Fundamental
- Price
- SBLK $18.71
- BLTE $82.46
- Analyst Decision
- SBLK Strong Buy
- BLTE Strong Buy
- Analyst Count
- SBLK 3
- BLTE 4
- Target Price
- SBLK $25.00
- BLTE $89.00
- AVG Volume (30 Days)
- SBLK 1.6M
- BLTE 107.6K
- Earning Date
- SBLK 11-19-2024
- BLTE 11-12-2024
- Dividend Yield
- SBLK 14.96%
- BLTE N/A
- EPS Growth
- SBLK 10.39
- BLTE N/A
- EPS
- SBLK 2.98
- BLTE N/A
- Revenue
- SBLK $1,220,003,000.00
- BLTE N/A
- Revenue This Year
- SBLK $29.89
- BLTE N/A
- Revenue Next Year
- SBLK $9.08
- BLTE N/A
- P/E Ratio
- SBLK $6.36
- BLTE N/A
- Revenue Growth
- SBLK 24.41
- BLTE N/A
- 52 Week Low
- SBLK $18.52
- BLTE $31.01
- 52 Week High
- SBLK $27.47
- BLTE $86.53
- Technical
- Relative Strength Index (RSI)
- SBLK 34.30
- BLTE 72.06
- Support Level
- SBLK $19.72
- BLTE $80.00
- Resistance Level
- SBLK $20.20
- BLTE $84.50
- Average True Range (ATR)
- SBLK 0.43
- BLTE 4.46
- MACD
- SBLK -0.01
- BLTE -0.22
- Stochastic Oscillator
- SBLK 9.41
- BLTE 83.18
About SBLK Star Bulk Carriers Corp.
Star Bulk Carriers Corp provides seaborne transportation solutions in the dry bulk sector. The company owns and operates dry bulk carrier vessels, which are used to transport bulk, such as iron ore, coal, grains, bauxite, fertilizers, and steel products. It owns a fleet of vessels that consists of Newcastlemax, Capesize, Post Panamax, Kamsarmax, Panamax, Ultramax, and Supramax. It generates revenues through the voyages it carries out.
About BLTE Belite Bio Inc
Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively lead to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout.